dm+d
Unassigned
New Medicines
Locally advanced or metastatic breast cancer
Information
New molecular entity
Odonate
Odonate
Development and Regulatory status
Discontinued
Discontinued
Discontinued
Mar 21Odonate is ending development of tesetaxel and closing business after the FDA deemed clinical data as unlikely to support approval [8].
Category
Taxane
Breast cancer is the second most common cancer worldwide, with an estimated 1.8 million new cases diagnosed per year. In Europe, an estimated 494,000 new cases are diagnosed and approximately 143,000 women will die of the disease each year, making it the leading cause of cancer death in women [1].
Locally advanced or metastatic breast cancer
Oral